Reimagining rare disease policies through a global lens by Lai, Austin
Reimagining rare disease policies
through a global lens
Communication | Editorial | Invited contribution | Perspective | Report | Review
Austin Lai
Cambridge Institute for Medical Research
University of Cambridge
Abstract
An estimated 400 million individuals suffer from rare diseases globally. Tackling rare diseases has historically
posed difficulties, including the lack of knowledge about their underlying causes, lack of resources for patients,
and fundamental inefficiencies at multiple stages along the pipeline, from basic science discovery to clinical
translation and diagnosis. The development of rare disorder therapeutics, often termed orphan drugs, faces a
unique set of challenges in clinical trials: difficulties in recruiting patients, difficulties in following conventional
clinical trial structure, as well as financial barriers for drug approval. Here, I argue for the creation of an
international organisation for rare diseases to coordinate a shared global patient registry and standard for
orphan drug approval. An initiative of such nature, with representation from experts and organisations in
the science, medicine, and patient-support industries will assist in overcoming the present challenges, whilst
accelerating progress and improving the experience during treatment of patients with rare disorders.
Science ⇒ Policy
Rare diseases altogether cause a large financial burden and personal suffering on an unignorable portion of
the population. Yet, our lack of understanding of these diseases and the scarcity of patients present unmet
challenges to developing and validating new therapies. I argue that the rare disease community can benefit
greatly from an international organisation that coordinates databases, patients, and new research globally.
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Introduction
By definition, rare diseases individually affect
a small proportion of the population, and this
has partly contributed to the historical lack of
attention directed towards this field. Yet, rare
disorders collectively affect roughly 260 to 400
million patients globally [1]. There are approxi-
mately 6,800 known rare disorders, affecting 25
million people in the U.S. alone, and nearly 30
million people in Europe [2]. For a significant
part of history, patients of rare diseases were left
helpless, without treatment options, due to a sys-
temic flaw that prevents significant drug discovery
for rare diseases.
In 1983, significant progress began with the
United States leading the way by introducing the
landmark Orphan Drug Act (ODA). The ODA
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clarifies the definition of rare disorders (or “orphan
diseases”) in the U.S. by defining rare diseases
as those affecting less than 200,000 Americans
[3]. The act also incentivises the industry to
develop orphan drugs by: providing seven-year
market exclusivity for such drugs; lowering devel-
opment costs through tax benefits, grants, and
application fee waivers; and allowing fast-track
development and approval [4].
In other countries, legislation for rare diseases
vary in the specific programmes introduced.
Japan established the National Programme on
Rare and Intractable Diseases in 1972. In the
early- to mid-2010s, several Latin American na-
tions such as Argentina, Brazil, and Chile intro-
duced national laws or ordinances for rare diseases
[5]. Notably, the introduction of Law 26,689 in
Argentina in 2011 established prevalence criteria
for rare diseases and mandated patient and data
registries as well as new programmes to improve
diagnosis and care for rare diseases.
In addition, there are programmes that operate
at an international level. In 2009, a collaborative
effort between the European Commission and the
National Institutes of Health in the United States
led to the establishment of the International Rare
Disease Research Consortium (IRDiRC)—which
unites other national and international, for-profit,
non-profit and governmental organisations for
greater collaboration to advance rare disease re-
search. [6].
Current Challenges
While the introduction of legislation such as
the Orphan Drug Act has opened doors to new
opportunities to develop therapies for rare dis-
eases (pharmaceutical, surgical, radiation, phys-
ical, mental health support therapies or other-
wise), many challenges remain. Broadly, the prob-
lems tend to aggregate at three nodes along the
pipeline from research to clinical translation:
1. lack of access to information for patients;
2. barriers against clinical trials for orphan
drugs; and
3. unreliable data on rare disease preva-
lence.
Improvements are possible with policy and struc-
tural changes regulating research grants and clin-
ical trial design.
The scarcity of patients with specific rare dis-
eases, or subtypes of rare disorders, significantly
impairs the ability to recruit sufficient pools of
patients for clinical trials. Consequently, the low
availability of patients hinders the success and
efficacy of clinical trials. First, small sample sizes
hinder the ability for physicians to draw definitive
conclusions from trials about the efficacy of the
drugs under examination. Moreover, logistical
and policy regulations further limit studies to
small geographic regions, exacerbating the prob-
lem of patient scarcity and further reducing the
scientific weight of the published results from
randomised controlled trials.
From a clinical perspective, when it comes to rare
diseases, there are two key problems. The first re-
lates to negative patient outcomes resulting from
slow or inaccurate patient diagnosis. According
to European and trans-Atlantic surveys, first-line
physicians lacking familiarity with rare diseases
are often unclear about the presenting symptoms,
so that they misdiagnose the patient with a more
familiar ailment and implement an incorrect treat-
ment, potentially allowing the disease to progress
to a more advanced stage [2]. The second re-
lates to a lack of understanding about disease
progression, complicating the determination of
the appropriate clinical trial endpoints validating
orphan drugs. In such cases, molecular biomark-
ers may be the necessary alternative [7]. Our
most recent understanding of rare disease mani-
festations and relevant biomarkers must be made
readily available for researchers and physicians
across the globe, to not only optimise diagnosis,
but standardise the endpoints for clinical trials
conducted in different countries.
To further complicate the problem, the prevalence
of many rare disorders is ill-researched, leading to
an inaccurate (often overestimated) understand-
ing of the patient population size for a specific
rare disorder. This can lead to a lack of return
on investments that companies have devoted to-
wards validating therapies for specific diseases,
thus making them less likely to do so again in
the future. The overestimation of rare disease
prevalence has been attributed most commonly
to the fact that studies regarding prevalence are
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done regionally, and often, only using hospital
data [7].
Some of the most valuable metrics in assessing
the state of rare disease diagnosis, treatment,
and care are the feedback and reflections from pa-
tients. A survey conducted in both the U.S. and
the U.K. examined the quality of patient care for
a wide range of rare disease [8]. Dishearteningly,
the survey found that around half of the rare
disease patients receive conflicting information
from different healthcare providers, with patients
receiving on average two to three misdiagnoses.
Furthermore, it takes on average seven to eight
years for patients with rare diseases to receive
a proper diagnosis [8]. These results altogether
suggest an urgent need to reconsider the man-
ner in which diagnostic criteria are organised for
healthcare professionals.
Policy Recommendations
Most challenges that remain today with rare dis-
ease policies can be addressed by a global effort
to unify policies for patients in areas of advocacy,
diagnosis, basic research, new drug development,
and clinical trials. These international efforts can
be accomplished through current organisations
such as the International Rare Disease Research
Consortium (IRDiRC).
Such an organisation would be led by a cohort
of leaders from the clinical, industrial, and aca-
demic fronts of rare disease research. Through
this organisation, a shared patient registry can be
established. This allows clinicians from one na-
tion to gain access to rare disease patient records
from another region or country, who would oth-
erwise not have been able to enrol in trials or
receive a similar level of healthcare. These pa-
tients can then be recruited by more clinical trials,
thereby benefitting both the study and the pa-
tients, while pushing progress on therapeutic de-
velopment. The sharing of patient registries and
other databases can also increase the accuracies
of the estimated prevalence for many rare disor-
ders, thus better informing the design of clinical
trials.
The committees within these existing interna-
tional organisations for rare diseases should also
work to standardise the requirements for the ap-
proval of orphan drugs. By doing so, each ap-
proved orphan drug designation would have a
greater geographical impact, serving more pa-
tients than they do under the current model,
with an added financial incentive to companies
involved in development.
Furthermore, the proposed global organisation
for rare diseases should include representation
from patient advocacy groups to strengthen the
communication between patients, physicians, and
governments. By facilitating patient-doctor com-
munication and promoting patient recruitment,
patient advocacy groups play a large role in the
success of clinical trials [9, 10]. This collaboration
can solidify our understanding of disease mani-
festation and lead to a more robust diagnosis
protocol, which can then be standardised across
countries and communicated to patient groups in
different regions.
Affecting hundreds of millions of patients, rare
diseases altogether impose a large family and fi-
nancial burden. It is therefore in the best interest
of the global community to agree on a new unify-
ing strategy that maximises the efficiency of our
time and efforts in combating rare disorders.
Suggested Further Study
Above, I argue that many of the current problems
can be addressed by the transnational sharing of
resources such as patient registries and databases;
by further promoting patient representation at
the global level; and by establishing an interna-
tionally consistent standard for the approval of
orphan drugs. This piece serves as a call to action
for further studies on the feasibility of these un-
dertakings and the most appropriate funding and
administrative strategies that should be employed
to overcomes these challenges. For instance, in
creating a globally accessible pool of rare disease
patients for clinical trials, a series of other needs
arise that require further funding. The travel
expenses of the patient as they participate in
clinical trials away from home will cumulate to a
significant sum that calls for additional support
from governmental and non-profit organisations.
To meet these financial needs, difficult questions
must be answered regarding the sources of this
funding, and the ethics behind each.
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Furthermore, the three major challenges men-
tioned above can be most efficiently tackled by
an international organisation for rare diseases.
Practically, it is most efficient to call on current
international rare disease organisations that can
expand their role and carry out these projects.
However, the determination of which interna-
tional organisation is most suitable to take on this
role requires further evaluation of their missions,
sources of funding, and governmental structures.
I argue that the IRDiRC is the most suitable on
the basis of its focus on coordinating research and
diagnostic goals across national governments and
non-governmental organisations (NGOs). Cur-
rently, the IRDiRC is funded by the European
Union through the European Joint Programme
on Rare Disease [11]. It is conceivable that this
funding scheme can be expanded to include the
World Health Organisation (WHO), U.S. govern-
ment, and NGOs that share a specific interest in
supporting clinical and research progress.
With further evaluation and careful implemen-
tation, these measures can strengthen the ties
within the global community of rare disease pa-
tients, researchers, and physicians, and further
accelerate the progress towards successful treat-
ment of rare disorders.
© 2021 The Author. Published by the Cambridge
University Science & Policy Exchange under the
terms of the Creative Commons Attribution License
http://creativecommons.org/licenses/by/4.0/,
which permits unrestricted use, provided the original
author and source are credited.
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